This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

07 March 2018

Hamilton, Bermuda – March 7, 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ), parent of Jazz Investments I Limited whose Secured Loan Note Programme is listed on the BSX, announced their participation in two investor conferences. The filing stated:

DUBLIN,March6,2018--JazzPharmaceuticalsplc(Nasdaq:JAZZ)todayannouncedthatthecompanywillbewebcastingitscorporatepresentationsattwoupcominginvestorconferences.

· CowenandCompany38th AnnualHealthcareConferenceinBoston,MAonTuesday,March 13, 2018 at8:00a.m. EDT /12:00p.m. GMT.Bruce Cozadd, chairman andchiefexecutiveofficer,willprovideanoverviewofthecompany and abusinessandfinancialupdate.

· BarclaysGlobalHealthcareConferenceinMiami,FLonWednesday,March14,2018at8:00a.m. EDT / 12:00 p.m. GMT.Matt Young, executive vice presidentand chieffinancialofficer,willprovidean overviewofthecompanyandabusinessandfinancialupdate.

Alive audiowebcast ofeachpresentation may beaccessedfrom theInvestors section ofthe JazzPharmaceuticalswebsiteathttp://www.jazzpharmaceuticals.com.Pleaseconnecttothewebsitepriorto the startof the presentationto ensure adequatetime for anysoftware downloads thatmaybenecessarytolistentothe webcast.

An archive of the webcast will be available for atleast one weekfollowing the presentation ontheInvestorssectionofthecompany’swebsiteathttp://www.jazzpharmaceuticals.com.

AboutJazzPharmaceuticals

JazzPharmaceuticalsplc(Nasdaq:JAZZ)isaninternationalbiopharmaceuticalcompanyfocusedonimprovingpatients’livesbyidentifying,developingandcommercializingmeaningfulproductsthataddressunmetmedicalneeds.The companyhasadiverseportfolioof productsandproductcandidateswith afocusinthe areasofsleep andhematology/oncology.Inthese areas,JazzPharmaceuticalsmarketsXyrem®(sodiumoxybate)oralsolution,Erwinaze®(asparaginaseErwiniachrysanthemi),Defitelio®(defibrotidesodium)andVyxeos®(daunorubicinandcytarabine)liposomeforinjectionintheU.S.andmarketsErwinase®andDefitelio®(defibrotide)incountriesoutsidetheU.S.Forcountry-specificproductinformation,pleasevisit http://www.jazzpharmaceuticals.com/products.Formoreinformation,pleasevisit http://www.jazzpharmaceuticals.com/andfollowusonTwitterat@JazzPharma.

JazzPharmaceuticalsContacts:

Investors:

KatheeLittrell

VicePresident,InvestorRelationsIreland,+3531 6347887

U.S., +1 650 496 2717

Media:

JacquelineKirby

VicePresident,CorporateAffairs&GovernmentRelationsIreland,+3531 6972141

U.S., +1 215 867 4910